MA01.06 Effects of the Immunotherapy Era on Maintenance Outcomes in Advanced Nonsquamous NSCLC: Subgroup Analysis of ECOG 5508

The ECOG 5508 (E5508) study, which enrolled patients from 2010-2015, evaluated pemetrexed, bevacizumab, or the combination as maintenance therapy for advanced nonsquamous non-small-cell lung cancer (NSCLC). Results showed that single-agent bevacizumab or pemetrexed were equally efficacious in regards to progression free survival (PFS) and overall survival (OS). Combination therapy improved PFS, but the difference in OS was not statistically significant. Treatment practice changed in 2015 with the approval of immune checkpoint inhibitors for second line therapy in metastatic NSCLC with progression on or after platinum based therapy.